Literature DB >> 8421174

Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi.

B J Holaday1, M M Pompeu, T Evans, D N Braga, M J Texeira, A de Q Sousa, M D Sadick, A W Vasconcelos, J S Abrams, R D Pearson.   

Abstract

Patients from across the spectrum of clinical manifestations of Leishmania chagasi infection were evaluated for in vitro correlates of immunity. Peripheral blood mononuclear cells were assayed for parasite-specific lymphoproliferation, cytokine generation, and the capacity to activate autologous macrophages to kill intracellular amastigotes. Patients with acute kala-azar were generally unreactive in each of these assays. Children with subclinical infection demonstrated relatively low levels of proliferation and interferon-gamma production, but none went on to develop overt kala-azar during the study. Patients evaluated after therapy for kala-azar demonstrated yet higher levels of lymphoproliferation and cytokine generation and produced low but significant levels of cytokines in vitro in response to parasite antigens, but not during the activation of infected macrophages. Finally, peripheral blood mononuclear cells from adults with positive delayed-type hypersensitivity responses and no history of kala-azar showed the broadest reactivity in vitro. These patients' cells generated the largest amounts of activating cytokines in vitro during the activation of autologous macrophages to a leishmanicidal state.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8421174     DOI: 10.1093/infdis/167.2.411

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis.

Authors:  I Suffia; B Ferrua; X Stien; B Mograbi; P Marty; D Rousseau; K Fragaki; J Kubar
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Further evidences on a new diagnostic approach for monitoring human Leishmania (L.) infantum chagasi infection in Amazonian Brazil.

Authors:  Fernando Tobias Silveira; Ralph Lainson; Adelson Alcimar Almeida De Souza; Marliane Batista Campos; Liliane Almeida Carneiro; Luciana Vieira Rego Lima; Patrícia Karla Santos Ramos; Cláudia Maria de Castro Gomes; Marcia Dalastra Laurenti; Carlos Eduardo Pereira Corbett
Journal:  Parasitol Res       Date:  2009-11-28       Impact factor: 2.289

4.  Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

Authors:  M S Duthie; J Guderian; A Vallur; A Bhatia; P Lima dos Santos; E Vieira de Melo; A Ribeiro de Jesus; M Todt; D Mondal; R Almeida; S G Reed
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-31       Impact factor: 3.267

5.  Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. The AIDS Vaccine Evaluation Group.

Authors:  T G Evans; T Fitzgerald; D C Gibbons; M C Keefer; H Soucier
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

6.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

7.  Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasis.

Authors:  Abdurrahim Kocyigit; Selahaddin Gur; Mehmet S Gurel; Vedat Bulut; Mustafa Ulukanligil
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

8.  Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes.

Authors:  F Afrin; N Ali
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

9.  Potential role for interleukin-10 in the immunosuppression associated with kala azar.

Authors:  B J Holaday; M M Pompeu; S Jeronimo; M J Texeira; A de A Sousa; A W Vasconcelos; R D Pearson; J S Abrams; R M Locksley
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

10.  Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis.

Authors:  G D Miralles; M Y Stoeckle; D F McDermott; F D Finkelman; H W Murray
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.